Review



p815 leukemia cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC p815 leukemia cells
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    P815 Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1026 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 leukemia cells/product/ATCC
    Average 96 stars, based on 1026 article reviews
    p815 leukemia cells - by Bioz Stars, 2026-05
    96/100 stars

    Images

    1) Product Images from "Mitochondrial complex II orchestrates divergent effects in CD4 + and CD8 + T cells"

    Article Title: Mitochondrial complex II orchestrates divergent effects in CD4 + and CD8 + T cells

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI194134

    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Flow Cytometry, Derivative Assay, Injection, Control, Two Tailed Test, MANN-WHITNEY



    Similar Products

    p815 leukemia cells  (ATCC)
    96
    ATCC p815 leukemia cells
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    P815 Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p815 leukemia cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    p815 leukemia cells - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    luciferase p815 cell line p815 leukemia cells  (ATCC)
    96
    ATCC luciferase p815 cell line p815 leukemia cells
    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with <t>P815</t> cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Luciferase P815 Cell Line P815 Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/luciferase p815 cell line p815 leukemia cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    luciferase p815 cell line p815 leukemia cells - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Journal: The Journal of Clinical Investigation

    Article Title: Mitochondrial complex II orchestrates divergent effects in CD4 + and CD8 + T cells

    doi: 10.1172/JCI194134

    Figure Lengend Snippet: ( A ) B6 and BALB/c mice were transplanted with WT or SDHA-KO T cells. Survival rate and clinical GVHD score are shown (syngeneic n = 8/group, allogeneic n = 10/group). ( B – D ) BALB/c mice received HCT with P815 cells (MHC class I + class II – ). ( B ) BALB/c mice received syngeneic or allogeneic T cells from WT or SDHA-KO mice and were infused concurrently with 1.0 × 10 3 luciferase + P815 cells. ( C ) Tumor-related mortality (syngeneic n = 5, allogeneic n = 11/group) and clinical GVHD score ( n = 5/group). ( D ) Representative bioluminescence images and tumor burden on day 14 after HCT ( n = 3–10/group). ( E ) BALB/c mice received HCT (WT or SDHA-KO B6 → BALB/c). Representative flow cytometry images and Annexin V + 7-AAD + cells in donor-derived (H-2Kb + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 6/group). ( F ) Representative flow cytometry measuring proliferation of donor-derived (H-2Kb+CD45.2 + ) CD4 + and CD8 + T cells day 7 after HCT ( n = 3–6/group). ( G ) Representative flow cytometry images and granzyme A and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD8 + T cells day 7 after HCT ( n = 3–10/group). ( H ) Representative flow cytometry images and granzyme A, granzyme B, and perforin levels in donor-derived (H-2Kb + CD45.2 + ) CD4 + T cells day 7 after HCT ( n = 3–10/group). ( I ) WT and SDHA-KO mice were inoculated with B16-F10 melanoma cells on day 0 and injected with anti–PD-1 or isotype control antibody on days 7, 10, 13, and 16. Tumor growth was measured ( n = 6–9/group). Two-tailed Mann-Whitney U test for GVHD score and Annexin V + 7-AAD + , Mantel-Cox log rank test for survival, 1-way ANOVA with Tukey’s post hoc test ( D and F – H ), and 2-way ANOVA with Tukey’s post hoc test ( I ) were used (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Article Snippet: P815 leukemia cells (catalog TIB-64) were purchased from ATCC and were transduced with luciferase ( ).

    Techniques: Luciferase, Flow Cytometry, Derivative Assay, Injection, Control, Two Tailed Test, MANN-WHITNEY